Anchored in work constructing protein-polymer conjugates using atom transfer radical polymerization (ATRP) chemistry undertaken by two of the firm's founders at Carnegie Mellon, BioHybrid Solutions LLC is addressing use of proteins across a wide variety of industries through the firm's polymer-based protein-engineering platform. The firm's efforts organize around designing and developing polymers that can be tailor made to stabilize proteins under specific conditions and for particular applications - effectively BHS is developing next-generation biopolymer hybrids, tailoring the activity and stability of proteins and enzymes for a wide range of applications including therapeutics, bioenergy, industrial catalysis, biosensors, and medical devices. BHS is focused on opportunities in therapeutics, biocatalysis, diagnostics, and devices. Polymer-modified enzymes dramatically improve biocatalytic processes, resulting in higher throughput, less waste, and lower costs. In therapeutics, polymer-modified proteins can open new routes of administration (e.g. injectable to oral), improve pharmacokinetics, and reduce immunogenicity. Novel biosensors, diagnostics, and devices are made possible through advanced protein stabilization and functionalization.
